NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) 1985 NO. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) 1985 NO. 320 - TABLE OF PROVISIONS 1. Commencement 2. Principal Regulations 3. Supply of pharmaceutical benefits on prescription 4. Repeat authorizations 5. Schedule 1 6. Schedule 2 7. Schedule 3 8. Schedule 5 SCHEDULE 1 SCHEDULE 2 SCHEDULE 3 SCHEDULE 4 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 1 Commencement 1. These Regulations shall come into operation on 1 December 1985. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 2 Principal Regulations 2. In these Regulations, "Principal Regulations" means the National Health (Pharmaceutical Benefits) Regulations. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 3 Supply of pharmaceutical benefits on prescription 3. Regulation 21 of the Principal Regulations is amended - (a) by omitting from paragraph (1) (c) "6 months" and substituting "12 months"; and (b) by omitting from paragraph (2) (e) "6 months" and substituting "12 months". 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 4 Repeat authorizations 4. Regulation 26 of the Principal Regulations is amended by omitting from paragraph (2) (d) "6 months" and substituting "12 months". 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 5 Schedule 1 5. Schedule 1 to the Principal Regulations is amended as set out in Schedule 1. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 6 Schedule 2 6. Schedule 2 to the Principal Regulations is amended as set out in Schedule 2. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 7 Schedule 3 7. Schedule 3 to the Principal Regulations is amended as set out in Schedule 3. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 8 Schedule 5 8. Schedule 5 to the Principal Regulations is amended as set out in Schedule 4. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 1 SCHEDULE 1 Regulation 5 AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. After item 345 insert the following item: "345A Dextromoramide Tartrate Injection". 2. Omit item 887. 3. After item 916 insert the following item: "916A Phenytoin Tablets". 4. After item 1003 insert the following item: "1003A Protriptyline Tablets". 5. Omit item 1272. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 2 SCHEDULE 2 Regulation 6 AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. Omit item 12. 2. Omit item 173, substitute the following item: "173 Morphine Sulphate, B.P. Tacrine Hydrochloride with Morphine Sulphate, B.P.". 3. Omit item 222, substitute the following item: " 222 Senega and Ammonia Mixture - ". 4. Omit item 254. 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 3 SCHEDULE 3 Regulation 7 AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. After item 98 insert the following item: "98A Funnel-Web Spider Antivenom". 2. Omit item 109. 3. Omit item 123, substitute the following item: "123 Insect Allergen Extract - Paper Wasp Venom". 4. Omit item 200. 5. Omit item 219, substitute the following item: "219 Senega and Ammonia Mixture". 1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 4 SCHEDULE 4 Regulation 8 AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. Omit item 5, substitute the following item: "5 'ALFARE' With the written authority of the Secretary - Biliary atresia Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months". 2. Omit item 10. 3. Omit item 13. 4. Omit item 26, substitute the following item: "26 (1) Calcium Carbonate, B.P. Hypocalcaemia (2) Calcium Carbonate, B.P., with Osteoporosis Calcium Lactate-Gluconate Proven malabsorption". 5. Omit item 27, substitute the following item: "27 Calcium Folinate Antidote to folic acid antagonists". 6. Omit item 28. 7. Omit item 29, substitute the following item: "29 Captopril Moderate or servere hypertension For the continuing treatmen t of severe refractory cardiac failure where treatment with captopril was initiated in a hospital". 8. Omit item 34. 9. Omit item 38. 10. Omit item 43, substitute the following item: "43 (1) Chlorpromazine Elixir, B.P. Chorea (2) Chlorpromazine Injection, B.P. Hyperactive states of organic or toxic delirium (3) Chlorpromazine Suppositories, Major psychoses including - B.P. Major organic psychoses including arteriopathic (4) Chlorpromazine Tablets, B.P. dementia Manic depressive disorder manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years". 11. Omit item 48, substitute the following item: "48 (1) Cloxacillin Capsules, B.P. Infections due to the presence of (2) Cloxacillin Sodium, B.P., with penicillin-resistant staphylococci Purified Water, B.P. Osteomyelitis". 12. Omit item 54, substitute the following item: "54 Dantrolene Sodium Treatment of chronic spasticity". 13. Omit item 56, substitute the following item: "56 Demeclocycline Capsules, B.P. Syndrome of inappropriate antidiuretic hormone secretion, caused otherwise than by treatment with a drug". 14. Omit item 60, substitute the following item: "60 (1) Dextromoramide Tablets, B.P. Disabling pain associated with proven malignant (2) Dextromoramide Tartrate, B.P. neoplasia". 15. Omit item 67. 16. Omit item 73, substitute the following item: "73 Etretinate With the written authority of the Secretary - Treatment initiated in a hospital of - Chronic disfiguring discoid lupus erythematosus Darier's disease Erythrokeratoderma Pityriasis rubra pilaris Severe congenital ichthyosis (lamellar, bullous and sex linked) Severe intractable psoriasis Severe palmo-plantar keratoderma For the continuing treatment of a patient who has already received, for more than 6 months, therapy with etretinate for a condition listed above". 17. Omit item 74, substitute the following item: "74 (1) Flucloxacillin Capsules, B.P. Infections due to the presence (2) Flucloxacillin Sodium, B.P., of penicillin-resistant with Purified Water, B.P. staphylococci Osteomyelitis". 18. Omit item 77, substitute the following item: "77 (1) Fluphenazine Decanoate Chorea Injection, B.P. Hyperactive states of organic or toxic delirium (2) Fluphenazine Hydrochloride, B.P. Major psychoses including - (3) Fluphenazine Tablets, B.P. Major organic psychoses including arteriopathic dementia Manic depressive disorder manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness". 19. Omit item 80, substitute the following item: "80 Fusidic Acid, B.P. For use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence". 20. Omit item 85, substitute the following item: "85 (1) Haloperidol, B.P. Chorea (2) Haloperidol Tablets, B.P. Hyperactive states of organic or toxic delirium Major psychoses including Major organic psychoses including arteriopathic dementia Manic depressive disorder manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness". 21. Omit item 93, substitute the following item: "93 (1) 'KETOVITE' Liquid With the written authority of the Secretary - (2) 'KETOVITE' Tablets Chronic cholestasis Galactosaemia Persistent monosaccharide intolerance Phenylketonuria Tyrosinosis (hereditary) Use in association with a ketogenic diet". 22. Omit item 98, substitute the following item: "98 (1) Medroxyprogesterone Acetate, Breast cancer B.P., Injection, 50 mg in 1 mL Endometrial cancer Renal cell cancer". (2) Medroxyprogesterone Acetate, B.P., Injection, 500 mg in 2.5 mL (3) Medroxyprogesterone Acetate, B.P., Tablets, 100 mg 23. Omit item 104. 24. Omit item 105. 25. Omit item 110, substitute the following item: "110 Metronidazole, B.P. Prophylaxis in large bowel surgery Treatment in a hospital of acute anaerobic sepsis". 26. Omit item 115, substitute the following item: "115 (1) Nalidixic Acid Mixture, B.P. For use as a urinary (2) Nalidixic Acid Tablets, B.P. antiseptic in patients with neurogenic bladder Urinary tract infections where current clinical and bacteriological evidence confirm that nalidixic acid is the most appropriate therapeutic agent". 27. Omit item 119. 28. Omit item 120. 29. Omit item 129, substitute the following item: "129 (1) Penicillamine, B.P. Acute heavy metal intoxication (2) Penicillamine Tablets, B.P. Cystinosis Cystinuria with calculus formation Haemoglobinuria, paroxysmal cold Severe rheumatoid arthritis Wilson's disease (hepatolenticular degeneration)". 30. Omit item 131, substitute the following item: "131 Pericyazine Chorea Hyperactive states of organic or toxic delirium Major psychoses including - Major organic psychoses including arteriophatic dementia Manic depressive disorder - manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years". 31. After item 131 insert the following item: "131A Pethidine Tablets, B.P. With the written authority of the Secretary - Disabling pain associated with proven malignant neoplasia". 32. Omit item 132, substitute the following item: "132 Phenelzine Tablets, B.P. Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states". 33. Omit item 142. 34. Omit item 147. 35. Omit item 148, substitute the following item: "148 Propantheline Tablets, B.P. Chronic neurogenic incontinence of urine". 36. Omit item 152, substitute the following item: "152 Rifampicin, B.P. Prophylaxis of meningococcal disease in close contacts and carriers With the written authority of the Secretary - Leprosy in adults". 37. After item 153 insert the following item: "153A Socium Acid Phosphate, B.P., With the written authority of the Secretary - Compound Effervescent Tablets Familial hypophosphataemia Hypercalcaemia Vitamin D-resistant rickets". 38. Omit item 156, substitute the following item: "156 Sodium Fusidate, B.P. For use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence". 39. Omit item 167, substitute the following item: "167 Tetrabenazine Chorea not adequately controlled by other drug therapy". 40. Omit item 170, substitute the following item: "170 (1) Thioridazine Hydrochloride, Chorea B.P. Hyperactive states of organic or toxic delirium (2) Thioridazine Tablets, B.P. Major psychoses including Major organic psychoses including arteriopathic dementia Manic depressive disorder manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years". 41. Omit item 172, substitute the following item: "172 Tobramycin Injection, B.P. Infections where positive bacteriological evidence confirms that tobramycin is the most appropriate antibiotic Septicaemia, suspected or proven". 42. Omit item 174, substitute the following item: "174 Tranexamic Acid Tablets, B.P. Hereditary angio-oedema". 43. Omit item 175, substitute the following item: "175 Tranylcypromine Tablets, B.P. Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states". 44. Omit item 177, substitute the following item: "177 (1) Trifluoperazine Chorea Hydrochloride, B.P. Hyperactive states of organic or toxic delirium (2) Trifluoperazine Hydrochloride Tablets, Major psychoses including B.P. Major organic psychoses including arteriopathic dementia Manic depressive disorder manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stag) Radiation sickness Severe conduct disorders in patients under the age of 16 years". 45. Omit item 180. - NOTES 1985 No. 320*1* NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS*2* (AMENDMENT) *1*Notified in the Commonwealth of Australia Gazette on 29 November 1985. *2*Statutory Rules 1960 No. 17 as amended to date. For previous amendments see Note 2 to Statutory Rules 1985 No. 32 and see also Statutory Rules 1985 Nos. 32 and 184.